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ABSTRACT
Objectives Antiobesity drug (AOD) prescribing in children 
and young people (CYP) in primary care is rising with high 
rates of discontinuation. Little is known about prescribing 
in this group in terms of patient demographics and 
comorbidities, reasons for initiation and discontinuation, or 
adherence to national guidelines.
Design Questionnaire survey to general practitioners 
(GPs) identified using a nationally representative primary 
care database covering 6% of UK population.
Setting UK-wide primary care.
Participants Patients were eligible if prescribed an 
AOD aged ≤18 years between 2010 and 2012. A total of 
151 patients from 108 unique practices were identified 
via national prescribing database, with responses for 119 
patients (79%) from 84 practices; 94 of 119 (79%) were 
eligible for inclusion.
Primary and secondary outcomes Survey of GP 
prescribing habits of AODs to CYP. We audited orlistat 
usage against the National Institute for Health and Care 
Excellence (NICE) guidance.
Results 47% were prescribed metformin, 59% orlistat 
and 5% both drugs. Orlistat was largely prescribed by GPs 
independently (49/55 prescriptions, 89%) and metformin 
by GPs on specialist recommendation (12/44, 27%). 
Orlistat was largely prescribed in those over 16 years 
of age without physical comorbidities. Metformin was 
initiated for treatment of polycystic ovarian syndrome 
(70%), insulin resistance (25%) and impaired glucose 
control (9%). Median supply of metformin was 10.5 
months (IQR 4–18.5 months) and 2.0 months (1.0–4.0) for 
orlistat (p≤0.001). Drug terminations were largely due to 
families not requesting repeat prescriptions. NICE guidance 
adherence was low; 17% of orlistat prescriptions were 
initiated by specialists, and 56% had evidence of obesity-
related comorbidity. GPs reported lower confidence in 
prescribing AOD to CYP compared with adults (10-point 
Likert score median 3 vs 8, p<0.001).
Conclusions Prescribing of AOD in primary care is 
challenging with low adherence to NICE guidance. Further 
work is needed to better support GPs in the use of AOD in 
CYP.
InTRODuCTIOn
Little is known about use of medication for 
obesity in children and adolescents in the 
UK, particularly use in primary care. Orlistat 
is currently the only licensed antiobesity 
drug (AOD) in the UK since sibutramine was 
withdrawn due to concerns about cardiovas-
cular safety.1 2 However, the most commonly 
used drug for obesity in children and young 
people (CYP) is metformin, an antidiabetes 
drug used off-licence to treat the metabolic 
sequelae of obesity in CYP, although not 
formally classed as an AOD.3 4 Both orlistat 
and metformin appear to offer small bene-
fits for body mass index (BMI) loss in CYP; 
systematic reviews show small reductions 
in BMI compared with placebo, orlistat by 
0.83 kg/m25 and metformin by 1.4 kg/m2 (at 
6–12 months and 6 months, respectively).6
In the UK, the National Institute for Health 
and Care Excellence (NICE) guidance 
What this study hopes to add?
 ► Orlistat was largely prescribed independently by 
general practitioners to patients aged 16 years and 
over without physical comorbidities.
 ► Metformin was largely initiated by specialists for 
subjects with comorbidities, including polycystic 
ovarian syndrome, insulin resistance and impaired 
glucose tolerance.
 ► Adherence to the National Institute for Health and 
Care Excellence guidelines for orlistat prescribing to 
children and young people was low.
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What is already known on this topic?
 ► Orlistat and metformin are both used as antiobesity 
drugs (AOD) in children and young people, yet only 
orlistat is approved in this age group.
 ► UK primary care prescribing data show increasing 
use and high levels of drug discontinuation, with 
half of orlistat prescriptions not being continued 
beyond 1 month.
 ► One qualitative study eshowed frequent cessation 
by families independent of their doctors, usually 
because the perceived advantages did not outweigh 
the medication side effects.
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Box 1 Summary of 2014national Institute for Health and 
Care Excellence guidance for prescribing of orlistat to 
children and young people
1.8.4—Drug treatment is not generally recommended for children 
younger than 12 years.
1.8.5—In children younger than 12 years, drug treatment may be 
used only in exceptional circumstances, if severe comorbidities are 
present. Prescribing should be started and monitored only in specialist 
paediatric settings.
1.8.6—In children aged 12 years and older, treatment with orlistat 
is recommended only if physical comorbidities (such as orthopaedic 
problems or sleep apnoea) or severe psychological comorbidities are 
present. Treatment should be started in a specialist paediatric setting, 
by multidisciplinary teams with experience of prescribing in this age 
group.
1.8.7—Do not give orlistat to children for obesity unless prescribed 
by a multidisciplinary team with expertise in drug monitoring, 
psychological support, behavioural interventions, interventions to 
increase physical activity and interventions to improve diet.
1.8.8—Drug treatment may be continued in primary care, for 
example, with a shared care protocol if local circumstances and/or 
licensing allow.
1.9.2—Adults and children: If there is concern about micronutrient 
intake adequacy, a supplement providing the reference nutrient 
intake for all vitamins and minerals should be considered, particularly 
for vulnerable groups such as older people (who may be at risk of 
malnutrition) and young people (who need vitamins and minerals for 
growth and development).
1.9.11—If orlistat is prescribed for children, a 6-month to 12-month 
trial is recommended, with regular review to assess effectiveness, 
adverse effects and adherence.
recommends community-based lifestyle modification 
programmes as the first tier of weight management for 
childhood obesity, with pharmacotherapy as a second-
line treatment.2 Their guidance, summarised in box 1, 
only covers use of orlistat, which they state should be 
prescribed only in exceptional circumstances for those 
with obesity-related comorbidities (life-threatening in 
those under 12 years of age) and only prescribed by 
teams with expertise in these conditions.
Randomised trial data on orlistat and metformin come 
from specialist clinical settings and largely from outside 
the UK. Very little is known about how these AODs are 
prescribed and used in actual practice. Pharmacoepi-
demiology studies of AOD prescribing in primary care 
in the UK show increasing use of AODs, but also high 
levels of drug discontinuation, with approximately half 
the prescriptions of orlistat not being continued beyond 
1 month.5 The one qualitative study examining adoles-
cent use of AOD showed frequent cessation by fami-
lies independent of their doctors, usually because the 
perceived advantages did not outweigh the medication 
side effects that they endured with often minimal profes-
sional support.7 These data suggest that the effectiveness 
of AOD in ‘real life’ settings may be considerably less 
than shown in trials, and suggest a need to identify strate-
gies to improve the effectiveness of AODs for CYP.
We undertook a questionnaire survey of general practi-
tioners (GPs) prescribing AODs to CYP to better under-
stand their use in primary care in the UK. We sought to 
characterise patient demographics, quantify adherence 
to NICE guidance and identify primary care percep-
tions of AOD with the long-term aim of optimising AOD 
prescribing and efficacy.
MATERIAlS AnD METHODS
We used routinely collected primary care data from The 
Health Improvement Network (THIN) database to iden-
tify CYP aged up to and including 18 years prescribed 
orlistat or metformin between 31 May 2010 and 31 May 
2012. We excluded patients prescribed metformin for 
type 2 diabetes.
THIN covers approximately 6% of the UK population, 
with 3.6 million active patients from 587 general practices 
using the Vision General Practice System.8 These prac-
tices are broadly representative of practices in the UK in 
respect of patients’ demographics and characteristics.9 
Questionnaire administration was undertaken by THIN 
Additional Information Services (THIN AIS), an inde-
pendent research organisation affiliated with THIN, with 
data protection firewalls.
A paper questionnaire was sent to the GP practices of 
all identified CYP to collect patient-level data (see online 
supplementary appendix file 1 for full questionnaire). 
The questionnaire was designed by two paediatricians, 
an academic GP, a psychologist, a pharmacist and a GP 
representative following recommendations for good 
practice in survey research.10 GPs were contacted up to 
three times over 3 months until the questionnaire was 
returned. GPs received a £35 payment for each completed 
and returned questionnaire. THIN AIS anonymised ques-
tionnaires prior to analysis by the study team.
Year of birth, practice ID and region were provided 
by THIN AIS. All other data were provided by GPs 
using existing medical records, including ethnicity. We 
assumed AOD termination if no prescription had been 
issued within 3 months of the survey. Age at first prescrip-
tion was calculated from the midpoint of birth year, as 
month and day of birth were not provided due to data 
protection restrictions.
BMI and zBMI were calculated from GP-derived height 
and weight measurements using the LMS method and 
UK reference data.11 We audited orlistat use against 
NICE 2006 recommendations, which remain unchanged 
in the 2014 update, bar some text clarifications.2 12 For 
audits against NICE criteria only, we assumed birth date 
of 1 January to ensure that no subjects were misclassified 
as children if they were 18 years of age. Questionnaire 
responses were read by two researchers and any differ-
ences agreed.
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Figure 1 Patient sampling. THIN = The Health Improvement 
Network, GP = general practitioner, AOD = anti-obesity drug.
Table 1 Demographics and comorbidities by drug
Metformin Orlistat
n (total, % GP-initiated) 44 (27%) 55 (89%)
Female (n, %) 40 (91%) 46 (84%)
BMI (mean kg/m2, SD) 35.9 (6.1) 37.6 (6.5)
zBMI (mean, SD) 3.2 (0.7) 3.2 (0.6)
Median age (range) 15.7 (6.5–19.2) 17.3 (13.8–18.8)
<12 years (n) 5 0
12–15.9 years (n) 19 9
16–17.9 years (n) 16 29
≥18 years (n) 4 17
Comorbidities (n,%)
Hypertension 1 (2%) 0
Hyperinsulinism/insulin 
resistance
13 (30%) 0
Type 2 diabetes 0 3 (5%)
Dyslipidaemia 1 (2%) 3 (5%)
Emotional distress 12 (27%) 17 (31%)
Sleep apnoea 0 1 (2%)
Polycystic ovarian 
syndrome
32 (73%) 6 (11%)
Orthopaedic issues 3 (7%) 3 (5%)
Pervasive 
developmental disorder
3 (7%) 0
Hypothyroidism 1 (2%) 3 (5%)
BMI, body mass index; 
Analyses
Analyses were conducted using STATA V.11.0. Simple 
descriptive statistics were used for the majority of data. 
Duration of drug use was compared using Wilcoxon-
Mann-Whitney test (highly skewed data) and paired 
Likert scores using Wilcoxon signed-rank test.
Handwritten free-text comments were read and coded 
using a general thematic coding methodology.13 Models 
were developed through an iterative process, in which 
the initial model was reviewed using constant compar-
ison techniques (in which successive items of data are 
appraised and compared to ensure the code is reflective 
of all) and the models revised accordingly.
RESulTS
Patient demographics
Figure 1 summarises patient sampling; 151 patients 
were identified on THIN database from 108 unique GP 
practices, with 79% GP response rate (119 of 151 iden-
tified patients) from 84 unique practices. A total of 94 
subjects were eligible (86% female, 45% British, 31% 
white/Caucasian, 4% Asian, 4% other, 16% unknown 
ethnicity). The majority came from England (79%), with 
the remaining from Wales (12%), Scotland (7%) and 
Northern Ireland (2%).
A total of 99 AOD initiations occurred in 94 subjects 
(five subjects were prescribed both orlistat and 
metformin), consisting of 44 metformin (47% of sample) 
and 55 orlistat (59%) prescriptions. Drugs were initiated 
in 68 practices, with 46 practices prescribing one drug 
each, 15 practices two drugs each, 6 practices three drugs 
each and 1 practice prescribing five drugs.
Table 1 summarises baseline demographic and comor-
bidities by drug. Comorbidities appeared higher in 
those taking metformin. BMI and zBMI data were avail-
able for 91% (40/44) prescribed metformin and 89% 
(49/55) prescribed orlistat. All had BMI above the 98th 
centile (>2 SD). Prescriptions for metformin and orlistat 
increased with age, with orlistat largely prescribed to 
those aged 16 years or above.
Drug initiation
Figure 2 summarises the frequency of drug prescription 
by age and drug initiator; 89% (49/55) of orlistat and 
27% (12/44) metformin prescriptions were initiated in 
primary care independent of specialist advice. Orlistat 
was recommended by paediatricians (n=3), an adult 
physician, lipid clinic and dietitian, and metformin by 
paediatricians (n=19), gynaecologists (7), adult physi-
cians (4) and endocrinologists (1).
Indications for metformin initiation were obesity 
together with (1) polycystic ovarian syndrome (70%, 
31/44), (2) insulin resistance (25%, 11/44), (3) 
impaired glucose tolerance/impaired fasting glucose 
(9%, 4/44) and (4) obesity without known comorbidity 
(7%, 3/44).
Drug monitoring
Medication monitoring in primary care was under-
taken in 67% where initiated independently and 26% 
on specialist recommendation. GPs were made aware 
of adverse drug effects by two patients, both prescribed 
metformin; one had diarrhoea and the other nausea.
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Figure 2 Bar graph summarising age at initiation by drug 
and initiator. GP, general practitioner.
Figure 3 Kaplan-Meier survival curve demonstrating 
treatment duration of metformin and orlistat. Figure shows 
proportion still actively prescribed antiobesity drug for orlistat 
and metformin by time since initiation, beginning from time 0 
(100% active prescriptions) out to 85 months (longer active 
prescription).
Drug duration and termination
Duration of drug prescription is summarised in figure 3. 
The median supply of metformin was 10.5 months (IQR 
4–18.5 months) compared with 2.0 months (1.0–4.0) for 
orlistat (p≤0.001). Over half of all metformin prescrip-
tions (25/44) but only 5% of orlistat prescriptions (3/55) 
were active at the time of survey, defined as a new prescrip-
tion issued within the preceding 3 months. There was a 
disparity between reported length of drug prescription 
and the amount of drug prescribed, suggesting non-con-
tinuous use at dose prescribed.
Twenty-seven patients had only a single prescription 
issued from primary care, being 45% (25/55) of all orli-
stat and 5% (2/44) metformin treatments. None of these 
single prescriptions were issued in the 3 months prior to 
the survey, and all were given a maximum of 1-month 
supply, making ongoing use highly unlikely.
The majority of all drug terminations were due to 
families not requesting repeat prescriptions (96% of 
orlistat and 89% metformin) rather than medically led 
terminations. GPs reported possible orlistat cessation 
in three cases due to lack of drug supply in pharmacies. 
Of four prescriptions actively terminated by a doctor 
(metformin=2, orlistat=2), two were due to lack of effi-
cacy, one for lack of drug adherence, and the other two 
for reasons unknown.
Adherence to nICE guidance
We restricted NICE compliance analysis to recommenda-
tions for children; 23 subjects were identified as definitely 
aged less than 18 years at drug initiation. All subjects 
were aged over 12 years (recommendation 1.8.4), and no 
participants were prescribed orlistat for over 12 months 
(1.9.11).
The following criteria were partially met: First, four 
(17%) were prescribed orlistat following specialist advice 
(1.8.5). Recommending specialists were paediatricians 
(n=3) and an adult physician, with one known to be part 
of a specialist multidisciplinary team (1.8.7). All prescrip-
tions recommended by specialists were continued in 
primary care (1.8.8).
Second, comorbidities were reported in 57% of the 
sample (13/23) despite NICE requiring comorbidities to 
be present (1.8.6). These were emotional distress (7/23), 
hypothyroidism (3/23), type 2 diabetes (1/23), medul-
loblastoma (1/23), polycystic ovarian syndrome (1/23) 
or worsening of another chronic disease secondary to 
obesity (1/23). No patients had sleep apnoea. Low levels 
of comorbidity screening in primary care were reported, 
suggesting that higher number of comorbidities may have 
existed (6 of 23 were screened for psychosocial distress, 
5 for hypertension, 2 each for type 2 diabetes and dyslip-
idaemia, and none for sleep apnoea).
No patients were prescribed a multivitamin (1.9.2). We 
did not assess screening for micronutrient intake or risk 
of vitamin deficiencies.
Improving prescribing in primary care
GP confidence in prescribing AOD to CYP and adults is 
summarised in figure 4 and shows a skewed inverse rela-
tionship. Confidence was higher for prescribing to adults 
(median=8, IQR 8–9) than children (3, 1–5) (p<0.001).
GPs used NICE guidance (orlistat n=20, metformin 
n=7), British National Formulary (orlistat 17, metformin 
8), local prescribing guidelines (orlistat 8, metformin 
11) and specialist guidance (orlistat 1, metformin 7) to 
support prescribing.
GPs perceived that 27% (n=12) of patients prescribed 
metformin and 13% (7) prescribed orlistat benefited 
from the drug, with half (50% metformin, 53% orlistat) 
reporting not knowing if there had been any benefits for 
the patient.
Thirty-five GPs provided brief free-text reflections 
of their experiences prescribing orlistat (n=20) and 
metformin(n=14). Three main themes arose. First, 
the use of metformin was mostly ascribed to polycystic 
ovarian syndrome rather than as a weight loss drug. One 
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Figure 4 Histogram summarising general practitioner confidence in prescribing antiobesity drug to children and young people 
(left) and adults (right).
GP stated that (s)he “wouldn’t normally prescribe this 
just for weight loss.”
Second, there was controversy about whether AODs 
should be prescribed in primary care in this age group, 
with one saying (s)he “usually not prescribe for chil-
dren” and another saying (s)he avoided orlistat “where 
possible.” Metformin was used either “on advice of 
specialist only,” or had specialist follow-up after initiation.
Third, GPs noted concern about the efficacy of these 
drugs. “Inadequate counseling,” lack of drug availability 
and patient compliance (“clearly patient was not able to 
comply”) were hypothesised reasons for ineffectiveness.
Sixty-two GPs wanted improved support, primarily split 
into two main themes. First, they requested improved 
age-related guidance for prescribing AOD that is ‘real-
istic’, with ‘clear [and] concise’ advice including ‘flow 
diagrams’ and ‘stepwise advice’. This would include 
instructions on assessment prior to initiation, indication 
indications, contraindications, monitoring, safety advice, 
duration, targets and indications for stopping treatment. 
Second, they wanted improved guidance for managing 
patients with obesity, namely advice about lifestyle 
management and details of available interventions. GPs 
requested details of “non-drug treatments,” including 
“community support for adolescents” and “special clinics 
for monitoring and support of patients.” One GP high-
lighted that “non-drug treatments need to be key along-
side drug treatment.”
DISCuSSIOn
This is a detailed study of primary care prescribing 
of AODs in CYP at the individual patient level. Small 
numbers of prescriptions were issued in this age group, 
with most practices surveyed prescribing just a single 
AOD to a child or young person. However, clear patterns 
were detected that can help guide prescribing of current 
and future generations of AODs.
Recipients of an AOD were largely female, with 
two-thirds (65%) of the sample aged 16 or over. Two 
major prescribing patterns were seen: orlistat was 
largely initiated independently to those over 16 years, 
and metformin was largely recommended by special-
ists to girls with either polycystic ovarian syndrome or 
disturbances in glucose homeostasis. Comparison with 
NICE guidelines for orlistat showed low compliance 
with national prescribing recommendations, namely 
low prevalence of comorbidities and drug initiation 
without specialist advice. Given that most orlistat 
prescriptions were for those above 16 years, it could be 
hypothesised that those aged 16 years and over were 
treated as adults, with drugs prescribed in line with 
adult guidelines that do not necessitate presence of 
comorbidities.
Our findings augment the very limited existing data 
relating to AOD rates of initiation and cessation14 and 
experiences of CYP prescribed an AOD.7 A paired study 
by our research team investigating patient experiences 
of AODs found high levels of side effects, low levels of 
professional support managing these side effects, and 
ultimately families deciding to stop the AOD due to 
the disadvantages of the side effects outweighing the 
perceived benefits of the drugs.7 This contrasts with 
findings from this study where no patients actively 
discussed side effect profiles with their GPs, and GPs 
being aware of side effects in only two patients. This 
study does not explain the disconnect between the 
experiences of patients and clinicians, and further 
work should examine ways to support families so they 
are able to effectively manage the side effects of these 
drugs.
GPs reported low confidence in prescribing AOD to 
CYP, despite high levels of confidence when prescribing 
to adults. This fits with findings from our paired 
study, which showed that families notice this unease 
in primary care, and which can result in heightened 
familial concerns about AOD usage.7 GPs reported a 
desire for improved guidance on drug initiation and 
monitoring, and on lifestyle interventions, implying 
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low overall confidence in managing childhood obesity. 
These findings suggest that current national guide-
lines are inadequate for the needs of primary care, 
and further work is needed to understand how GPs 
can better support those with obesity.
Strengths and limitations
We used data from a nationally representative data set to 
identify patients prescribed an AOD with high rate of 
completion of questionnaires by GPs. Data collection relied 
on retrospective notes-based recall by GPs, increasing the 
likelihood of missing data. Individual item completion 
rates were variable, with some having only a few questions 
answered. We assumed that unanswered questions implied 
lack of evidence to support the questions. We were unable 
to ascertain the exact age of subjects, resulting in risk of 
misclassification bias, and we are likely to have underesti-
mated the number of subjects who were prescribed orlistat 
under 18 years of age. We limited the scope of project, and 
as such we are unable to comment on variation in drug 
dosing. We were unable to evaluate non-participant bias 
due to lack of information about individual GP practices.
COnCluSIOnS
Use of AOD including metformin in primary care is rare, 
particularly in men and those below 16 years. High rates of 
discontinuation were seen, primarily in those prescribed 
orlistat. Rates of compliance with NICE guidance for 
orlistat were low and GPs report low confidence in the 
use of AOD in this age group. Improved training and 
support for GPs is needed to guide AOD use in primary 
care, both for current and future generations of drugs.
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